4 years ago

Evox Therapeutics Secures £69.2M to Advance Exosome-Based Therapeutics

  • Oxford-based biotech company Evox Therapeutics has raised £69.2 million in a Series C funding round to advance its exosome-based therapeutics pipeline

  • The round was led by Redmile Group and joined by new investors OrbiMed and Invus, with participation from existing investors

  • The funding will support the clinical development of Evox's rare disease assets and the continued development of its DeliverEX platform.

      • ProblemBiotechnology

      "Create novel exosome-based biotherapeutics for the treatment of severe diseases with limited options for patients."

      Solution

      "Evox Therapeutics creates and modifies exosomes using molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, and plans to progress several rare disease assets into the clinic and continue developing its DeliverEX platform."

      Covered on